Drugs / HRS-717
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07806058 | Sep 2026 → Dec 2028 expected | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-717 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07806058 ↗ |